Pfizer-BioNTech said Thursday that, in a trial, a booster dose of its coronavirus vaccine in children ages 5 to 11 increased the level of antibodies that neutralized the original version of the virus and the Omicron variant.
Why it matters: If federal regulators verify the companies' claims, children over the age of 5 could gain access to boosters.
